Zai Lab delivered 17% year-over-year product revenue growth in Q4 2025, primarily driven by XACDURO and NUZYRA, while reducing net loss as revenue growth outpaced operating expense increases and foreign currency gains contributed positively.

Zai Lab reported a 9% year-over-year increase in total revenues to $110.0 million for the second quarter of 2025. The company significantly improved its operating loss by 28% year-over-year to $54.9 million, and by 37% on an adjusted basis, remaining on track to achieve profitability in the fourth quarter of 2025. Key product VYVGART showed strong growth with record patient utilization.

Zai Lab reported a 22% year-over-year increase in total revenues for the first quarter of 2025, reaching $106.5 million. Operating loss improved significantly, declining 20% year-over-year. The company remains on track to achieve profitability in the fourth quarter of 2025.

Zai Lab reported a strong fourth quarter and full year 2024, marked by a 66% increase in Q4 revenue to $109.1 million and a 50% increase in full-year revenue to $399.0 million. The company saw a 45% decrease in loss from operations for the quarter and is targeting $2 billion in revenue by 2028 and profitability in Q4 2025.

Zai Lab reported a strong third quarter with a 47% year-over-year increase in net product revenue, driven by VYVGART sales. The company also saw positive results from the China bridging study of KarXT and expects regulatory submissions in early 2025. Additionally, Zai Lab anticipates three product launches in mainland China by the end of 2024.

Zai Lab reported a strong second quarter with net product revenue of $100.1 million, representing 45% year-over-year growth. The company saw significant contributions from VYVGART, ZEJULA, and NUZYRA, and is on track to achieve profitability by the end of 2025.

Zai Lab reported a strong first quarter in 2024, with net product revenue of $87.1 million, representing 39% year-over-year growth (43% at CER). The launch of VYVGART contributed $13.2 million in sales. The company is preparing for potential launches and expects significant revenue growth and profitability by the end of 2025.

Zai Lab reported a full-year 2023 product revenue of $266.7 million, representing a 25% year-over-year growth. The company highlighted the successful launch of VYVGART in China and its inclusion in the NRDL. Zai Lab is focused on achieving corporate profitability by the end of 2025.

Zai Lab reported a net product revenue increase of 22% year-over-year, reaching $69.2 million in Q3 2023. The launch of VYVGART in China and continued growth of ZEJULA contributed to the revenue increase, while the company experienced a decreased net loss compared to the same period in 2022.

Zai Lab reported a 45% year-over-year increase in total product revenue, reaching $68.9 million in the second quarter of 2023. The company also gained approval for VYVGART in China and saw positive data for efgartigimod in CIDP. They anticipate corporate profitability by the end of 2025.

Zai Lab reported a 36% year-over-year increase in total product revenue, reaching $62.8 million for the first quarter of 2023. The company highlighted the expansion of its lung cancer franchise and global oncology pipeline, along with a strong cash position of $931.4 million.

Zai Lab Limited announced its full-year 2022 financial results, showcasing a 49.0% increase in total revenue compared to 2021, reaching $215.0 million. The company's marketed products, including ZEJULA, Optune, QINLOCK, and NUZYRA, experienced substantial sales growth. Zai Lab is preparing to launch at least 8 additional products and achieve overall corporate profitability by the end of 2025.

Zai Lab reported a strong third quarter with a new regional collaboration, significant revenue growth across commercial products, and progress towards achieving its 2022 corporate priorities. Total revenues were $57.5 million, a 33% increase year-over-year.

Zai Lab reported strong second-quarter results with continued revenue growth, particularly from ZEJULA. The company achieved key pipeline milestones, including the BLA acceptance of efgartigimod in China and positive topline results for the KarXT Phase 3 EMERGENT-2 trial. The company's cash position remains strong at $1.26 billion.

Zai Lab reported total revenues of $46.7 million for the first quarter of 2022, compared to $20.1 million for the same period in 2021. The net loss was $82.4 million, compared to $232.9 million for the same period in 2021. The company continues to advance its pipeline and commercial operations.

Zai Lab reported strong financial results for the year ended December 31, 2021. The company expanded its portfolio of potential first-in-class and/or best-in-class assets and made meaningful advances with its global pipeline. Commercial execution is gaining strong momentum for marketed products, including ZEJULA's inclusion in the NRDL for first-line ovarian cancer maintenance treatment.

Zai Lab and Blueprint Medicines announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 and BLU-701 for the treatment of patients with epidermal growth factor receptor (EGFR) -driven non-small cell lung cancer (NSCLC) in Greater China.

Zai Lab Limited announced financial results for the second quarter of 2021, reporting net product revenues of $36.9 million, compared to $11.0 million for the same period in 2020. The company reported a net loss of $163.3 million, or a loss per share attributable to common stockholders of $1.76.

Zai Lab reported a net product revenue increase to $20.1 million, driven by ZEJULA and Optune, along with strategic collaborations to strengthen their oncology and autoimmune franchises. The company also significantly bolstered its capital position with a global public offering, but reported a net loss of $232.9 million due to increased R&D expenses from new business development activities.

Zai Lab reported full-year 2020 revenues of $49.0 million, driven by sales of ZEJULA and Optune. The company highlighted key achievements including the inclusion of ZEJULA in the NRDL and progress in clinical development with multiple product candidates.